RESEARCH ARTICLE

Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

Audrey Valé e1, Marie Denis-Musquer2, Guillaume Herbreteau1, Sandrine Théoleyre1, Céline Bossard2, Marc G. Denis1*

1 Department of Biochemistry, Nantes University Hospital, Nantes, France, 2 Department of Pathology, Nantes University Hospital, Nantes, France

* marc.denis@chu-nantes.fr

Abstract

Screening for theranostic biomarkers is mandatory for the therapeutic management of cutaneous melanoma. BRAF and NRAS genes must be tested in routine clinical practice. The methods used to identify these alterations must be sensitive to detect mutant alleles in a background of wild type alleles, and specific to identify the correct mutation. They should not require too much material, since in some cases the available samples are small biopsies. Finally, they should also be quick enough to allow a rapid therapeutic management of patients. Sixty five consecutive formalin-fixed paraffin-embedded (FFPE) melanoma samples were prospectively tested for BRAF mutations with the VE1 (anti-BRAF V600E) antibody and for both BRAF and NRAS mutations with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges. Results were compared to our routine laboratory practice, allele specific amplification and/or Sanger sequencing and discordant cases confirmed by digital PCR. Excluding discordant by-design-mutations, system failures and DNA quantity or quality failures, BRAF IHC demonstrated an overall concordance of 89% for BRAF V600E mutation detection, the Idylla system gave a concordance of 100% for BRAF mutation detection and of 92.1% for NRAS mutation detection when compared to our reference. When discrepancies were observed, all routine results were confirmed by digital PCR. Finally, BRAF IHC positive predictive value (PPV) was of 82% and negative predictive value (NPV) of 92%. The Idylla cartridges showed a PPV and NPV of both 100% for BRAF mutation detection and a PPV and NPV of 100% and 87% respectively, for NRAS mutation detection. In conclusion, BRAF V600E immunohistochemistry is efficient for detecting the V600E mutation, but negative cases should be further evaluated by molecular approaches for other BRAF mutations. Since 3 NRAS mutations have not been detected by the Idylla NRAS-BRAF-EGFR S492R Mutation Assay, these cartridges should not be used as a substitute for traditional
molecular methods in the conventional patient therapeutic care process without the expertise needed to have a critical view of the produced results.

Introduction

Screening for theranostic biomarkers is mandatory for the therapeutic management of many types of cancer such as lung cancer, colorectal cancer and melanoma. In cutaneous melanoma, mutations of the \( \textit{BRAF} \) and \( \textit{NRAS} \) oncogenes are the most common genetic alterations with mutation rates of \(~40\%\) and \(~20\%\), respectively \([1, 2]\). Patients bearing a \( \textit{BRAF} \) \( V600 \) mutation may benefit from \( \textit{BRAF} \) and MEK inhibitors, but there is currently no approved targeted therapy for patients harboring \( \textit{NRAS} \) mutation \([3, 4]\). Nevertheless, \( \textit{NRAS} \) is a prognostic marker and a mechanism of acquired resistance to \( \textit{BRAF} \) inhibitors \([5]\). Therefore both \( \textit{BRAF} \) and \( \textit{NRAS} \) genes should be tested in routine clinical practice, along with \( \textit{KIT} \) for mucosal and acral melanoma \([6–8]\).

The methods used to identify these alterations must be sensitive to detect mutant alleles in a background of wild type alleles, and specific to identify the correct mutation. They should not require too much material, since in some cases the available samples are small biopsies, which are fixed in formalin and embedded in paraffin (FFPE). Finally, they should also be quick enough to allow a rapid therapeutic management of patients.

For \( \textit{BRAF} \) \( V600 \) testing, several methods have been developed: protein-based analysis and DNA-based analysis \([9]\). Protein-based analyses are mostly represented by IHC, using the monoclonal antibody VE1, validated to recognize the mutant \( \textit{BRAF} \) \( V600E \) protein \([10]\). DNA-based analyses include real-time PCR based assays \([11, 12]\), pyrosequencing \([13]\) and Next Generation Sequencing \([14]\). Real-time PCR assays are usually multiplexed amplifications designed to scan the most relevant and frequent therapeutic mutations while new generations of sequencing cover a large panel of mutations even beyond the therapeutic targets.

The turnaround-time of these methods is also of importance since treatment decisions are based on the results obtained. Therefore, rapid techniques detecting the most frequent therapeutic biomarker alterations are attractive. \( \textit{BRAF} \) IHC has been proposed as a screening tool for \( \textit{BRAF} \) \( V600E \) mutation \([13, 15, 16]\). A fully automated real-time PCR platform (Idylla system) has been designed to perform molecular analysis in \(~2\) hours. The Idylla \( \textit{BRAF} \) Mutation Assay has been shown to be efficient for testing FFPE melanoma samples \([17–19]\). Recently, new cartridges have been designed to allow the simultaneous detection of the most relevant \( \textit{BRAF} \) and \( \textit{NRAS} \) clinical alterations in a single assay, which is of interest for colorectal tumors and melanoma. Very few data are available, and most of these comparative studies have been conducted on selected FFPE samples \([20–22]\).

We thus conducted a prospective study comparing the performance of \( \textit{BRAF} \) Immunohistochemistry and Idylla \( \textit{NRAS-BRAF-EGFR S492R} \) Mutation Assay (RUO) to our standard reference methods for \( \textit{BRAF} \) and \( \textit{NRAS} \) mutations detection. We report here the results obtained on 65 consecutive unselected melanoma FFPE samples tested using these approaches.

Materials and methods

Patient samples

Sixty five consecutive FFPE tumor samples from 60 patients with metastatic melanoma were collected prospectively. Tumor content was assessed on hematoxylin- & eosin-stained sections. Serial 10-\( \mu \)m tumor sections were prepared for molecular analysis. At least one section was
used for molecular analysis according to our routine procedures. An additional section was used for testing on the Idylla platform. When possible, BRAF immunohistochemistry was performed using a remaining section. Tumor area was measured using the open source ImageJ software (NIH, Bethesda, Maryland). All assays were processed independently and blinded to mutation status determined by the other methods. Results were pooled for comparison at the end of the study.

The Ethics Committee (Comité de Protection des Personnes/CPP) considered that neither patient consent nor CPP approval was required for this non-interventional study.

**DNA extraction**

For routine BRAF/NRAS testing, DNA was purified following paraffin removal and macrodissection using the Maxwell RSC DNA FFPE kit on a Maxwell RSC system (Promega, Charbonnières-les-Bains, France). DNA concentration was quantified by spectrophotometry (NanoDrop ND-100 instrument, Thermo Fisher Scientific, Waltham, MA) and diluted to a final concentration of 5 ng/μl.

**Detection of BRAF V600 mutations with allele-specific amplification**

The most frequent BRAF mutations were detected by allele-specific amplification (ASA) as previously described [12] with minor modifications. We designed one common reverse primer (BRAF_AS; ATGGATCCAGACAACTGTTCAAAC) and two forward primers with a unique variation in their 3’ nucleotide such that each was specific for the wild type (V600; AGGTGATTGTTGCTAGCTACAGT) or the mutated variant (600E; AGGTGATTGTTGCTAGCTACAGA). Hence, 2 different PCR mixes were prepared: one for wild type allele detection and the second for mutant allele detection. Each mix contained 10 μl of LC480 Sybr green 2x master mix (Roche Diagnostics, Meylan, France), 0.5 μl of each primer (10 μM each), and 9 μl of the template (45 ng genomic DNA). Amplification conditions were optimized for the RotorGeneQ instrument (QIAGEN, Courtaboeuf, Ozyme, Saint Quentin en Yvelines, France) as follows: denaturation for 10 min at 95˚C; amplification for 45 cycles, with denaturation for 10 s at 95˚C, annealing for 15 s at 65˚C, and extension for 20 s at 72˚C.

The difference between the Ct values (ΔCt) of mutant and wild type allele amplifications was calculated. The lower the amount of mutated DNA in the sample, the higher the ΔCt value. This result was compared to a threshold which discriminates specific mutant amplification of PCR background. This ΔCt threshold was set at 7.

This assay can detect (but not distinguish) the V600E (c.1799T>A), the V600K (c.1798_1799GT>AA) and the V600D (c.1799_1800TG>AT) mutations, but not the V600R (c.1798_1799GT>AG) mutation. Therefore each sample was further analyzed by conventional Sanger DNA sequencing for nucleotide characterization or detection of BRAF mutations outside the codon 600 hotspot.

**Detection of BRAF exon 15 and NRAS exon 2 and 3 mutations by Sanger sequencing**

PCR amplifications were performed using the following primers: BRAF 15F (5’ - TCATAATGCTTGCTCTGATAGGA - 3’) and BRAF 15R (GGCCAATAATTTAATCAGTGGA) for BRAF exon 15, NRAS 2F (5’ - CCCCCAGGATTCTTACAGAA - 3’) and NRAS 2R (5’ - ATACACAGAGGAGCCTTCGC - 3’) for NRAS exon 2; NRAS 3F (5’ - CCCCCATACCCCTCCACACCC - 3’) and NRAS 3R (5’ - TGCCAAATACACAGAGGAGC - 3) for NRAS exon 3. All primers harbored universal M13 tags at their end. Cycling conditions were as follows: denaturation for 10 min at 95˚C; amplification for 40 cycles, with denaturation for 20 s at 95˚C, annealing for 30 s...
at 60˚C, and extension for 10 s at 72˚C. Sanger sequencing was performed using the universal M13 forward and reverse primers and Big Dye Terminator Chemistry v1 on an ABI3130XL Instrument. Sequences were analyzed using the Seqscape Software (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA).

**BRAF immunohistochemistry**

Immunohistochemistry was performed on 5-μm formalin-fixed paraffin-embedded (FFPE) sections from the same tissue block used for molecular testing. Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [10]. The immunological reaction was visualized with the Envision detection system (Dako) and AEC (3-amino-9 ethylcarbazole) as the chromogen, allowing the detection of VE1+ tumor cells even if these cells contained cytoplasmic melanin pigment. The sections were counterstained with Mayer’s hematoxylin. As a negative control, primary antibody was omitted. A BRAF V600E mutated melanoma served as positive external control on each immunostained slide. All Immunostainings were analyzed by two pathologists (MDM and CB) blinded to genetic data, and scored as follows: positive (with the percentage of VE1+ tumor cells) when viable tumor cells harbored cytoplasmic staining, negative when no staining or only scarce VE1+ tumor cells or only VE1+ macrophages.

**Detection of BRAF exon 15 and NRAS exons 2, 3 and 4 mutations with the Idylla molecular diagnostic system**

The Idylla system (Biocartis, Mechelen, Belgium) is a fully automated real-time PCR-based system for molecular diagnostics. Single-use cartridges contain all the necessary reagents to perform sample lysis, DNA extraction and real-time PCR amplification. The Idylla console software analyses the fluorescence signals and reports the presence or absence of a mutation. The Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges are designed to detect 25 different mutations: five mutations in codons 600 of the **BRAF** gene, 8 mutations in codons 12 and 13; 6 in codons 59 and 61; 4 in codons 117 and 146 of the **NRAS** gene and 2 mutations in codon 492 of the **EGFR** gene.

All tumor areas were macrodissected to be comparable to the laboratory’s standardized process. Samples which did not meet the recommendation (area) were not excluded. FFPE material was placed between two filter papers and transferred to the cartridge as per the manufacturer’s procedure. Finally, the cartridge was loaded onto the Idylla system for processing. All results were exported from the Biocartis console.

**Mutation detection by digital PCR**

Discordant samples were analyzed using a chip-based digital PCR platform, the Quant Studio 3D (Life Technologies, Thermo Fisher Scientific, Waltham, MA). The chip consists of 20,000 PCR wells in which DNA and PCR reagents are distributed. Taqman probe technology allows the detection of wild-type or a mutated or both DNA copies in each well. Fluorescence signal processing associated with the Poisson distribution allows absolute quantification of mutated and wild type copies. Mutation frequencies are determined by the ratio of mutated signals to wild type signals. This technique is considered more sensitive and accurate than conventional PCR methods, especially for the detection of low-frequency variants [23, 24].

The dPCR mastermix and Taqman assays were purchased from Thermo-Fisher Scientific. Twenty-five nanograms of FFPE DNA were added to the digital PCR mix before automatic distribution to a chip. After PCR amplification, raw data collected from the fluorescent reader...
were analyzed with a Visual Basic Application on Excel developed by our laboratory (unpublished data).

**Results**

**Prospective study cohort**

Sixty five consecutive FFPE tumor samples, collected from 60 patients with metastatic melanoma, were collected prospectively, representing the diversity of our laboratory’s routine recruitment (Table 1). Patient median age was 69 years (range 22–91). Most samples were surgical resections (n = 42, 65%). Both primary tumors (n = 32, 49%) and metastases (n = 32, 49%) were tested. In most cases, the tumor cell content of FFPE tissue sections was greater than 50% (n = 52, 80%), and the tumor area larger than 25 mm$^2$ (n = 41; 63%) (S1 Table), the

| Table 1. Characteristics of the 60 patients with metastatic melanoma and the 65 corresponding tumor samples tested. |
|---------------------------------------------------------------|
| **Gender**                                                                 |
| Male                                                | 38 (63) |
| Female                                              | 22 (37) |
| **Age**                                                                 |
| < 69                                                 | 32 (53) |
| > 69                                                 | 28 (47) |
| **Total patients**                                     | 60 (100) |
| **Tumor tissue origin**                                |         |
| Primary tumor                                         | 32 (49) |
| Metastasis                                           | 32 (49) |
| NA/ND                                                | 1 (2)   |
| **Sample Nature**                                     |         |
| Biopsy                                               | 22 (34) |
| Surgical sample                                      | 42 (65) |
| NA/ND                                                | 1 (1)   |
| **% of tumor cells**                                   |         |
| > 50%                                                 | 52 (80) |
| 25–50%                                               | 9 (14)  |
| 10–25%                                               | 4 (6)   |
| < 10%                                                | 0 (0)   |
| **Tumor area**                                         |         |
| < 25 mm$^2$                                           | 34 (52) |
| > 25 mm$^2$                                           | 30 (46) |
| NA                                                   | 1 (2)   |
| **Total area available for testing***                  |         |
| < 25 mm$^2$                                           | 23 (35) |
| > 25 mm$^2$                                           | 41 (63) |
| NA                                                   | 1 (1.5) |
| **Total samples**                                     | 65 (100) |

NA, information not available; ND, not determined
* Tumor area x number of tissue sections

https://doi.org/10.1371/journal.pone.0221123.t001
minimum tumor area required for an Idylla test. The 23 samples (35%) that did not meet this criterion were still analyzed by all three techniques.

**Performance of BRAF testing methods**

The results obtained with the 3 different techniques are presented in Table 2. All 65 samples were processed for BRAF testing with the techniques used in routine practice in our hospital: allele-specific amplification and Sanger sequencing. Complete results were obtained for 63 samples. The two remaining samples could only be assessed by ASA as DNA sequencing was not contributive. These sequencing failures were mostly due to poor DNA quality, complicating amplification of the 224-pb fragment for BRAF sequencing, whereas the ASA fragment was only 75-pb long. Using this approach, BRAF mutations were detected in 23 out of the 65 samples (35%), which is in line with the frequency of BRAF mutations in metastatic melanoma [1, 2].

These 65 samples were also tested using the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges. The test was not contributive in 2 cases (3.1%): one test failed due to insufficient material and one due to a software error. BRAF mutations were detected in 21 out of the 63 contributive samples (33%).

Finally 60 of the 65 samples were available for BRAF V600E assessment by IHC. A BRAF mutation was detected in 17 of the 60 tested samples (28%). As expected BRAF IHC did not detect any of the BRAF c.1798_1799delinsAA (V600K) mutations.

The discrepancies observed were further investigated by digital PCR. This method allows both absolute and relative quantification of low variant allele frequency (VAF), ensuring equal

| Table 2. Comparison of BRAF and NRAS results by allele specific amplification, Sanger sequencing, IHC and Idylla testing. |
|---|

| BRAF IHC | B BRAF Idylla |
|---|---|
| N | P | NT | All | No mutation | BRAF V600 | Insufficient material | Cartridge failure | All |
|---|---|---|---|---|---|---|---|---|
| BRAF ASA +Sanger sequencing | WT | 38 | 0 | 4 | 42 | 41 | 1 | 42 |
| | BRAF V600X | 0 | 1 | 0 | 1 | 1 |
| | BRAF V600E | 3 | 13 | 1 | 17 | 17 |
| | BRAF V600K | 5 | 0 | 0 | 5 | 4 |
| | All | 46 | 14 | 5 | 65 | 42 | 21 | 1 |

| NRAS Idylla |
|---|
| N | P | NT | All | No mutation | Insuff. material | Cartridge failure | All |
|---|---|---|---|---|---|---|---|
| NRAS Sanger sequencing | WT | 20 |
| | NT (BRAF mutated) | 22 | 1 | 23 |
| | NRAS Q61R | 2 | 7 | 9 |
| | NRAS Q61K | 5 | 5 |
| | NRAS Q61L | 1 | 2 | 3 |
| | NRAS Q61_E62delinsHK | 1 |
| | NRAS G13X | 1 |
| | NRAS G60E | 1 |
| | Not Contributive | 1 | 1 | 2 |
| | All | 48 | 14 | 1 | 65 |

N, Negative; P, Positive; NT, Not Tested
* Nucleotide characterisation by Sanger sequencing failed

https://doi.org/10.1371/journal.pone.0221123.t002
if not better performance than ASA or Idylla testing. The results are presented in Fig 1. One sample (#23) could not be confirmed as the DNA was too degraded; otherwise, all in-house assay results were confirmed by digital PCR. Finally we observed 3 false BRAF negative results (Fig 1A) and 3 false BRAF positive results with IHC (Fig 1B). For these 3 latter cases, IHC was repeated and turned out to be negative on a second read. DAB (3,3'-Diaminobenzidine) instead of AEC had been used as chromogen on the first tissue sections, generating false positive staining (Fig 2). Therefore, these 3 cases were subsequently considered as true negative results (Table 2). The details of all confirmed discordant BRAF genotypes are presented on Table 3.

Fig 1. Discordance analyses by digital PCR. A. Control of samples found positive for BRAF mutation by ASA/Sequencing but negative by IHC. B. Control of samples found negative for BRAF mutation by ASA/sequencing and positive by IHC (wrong chromogen used). C. Control of samples found positive for NRAS mutation by sequencing but negative by Idylla. Yellow dots correspond to wild type DNA copies (BRAF, panels A and B; NRAS, panel C). Green dots correspond to mutated DNA copies (BRAF V600E, panels A and B; NRAS Q61R, panel C). Grey dots correspond to empty wells.
For performance analysis, 5 discordant-by-design mutations (BRAF V600K) were excluded from BRAF IHC evaluation, and 2 from BRAF/NRAS Idylla test performance analysis. The cartridge failure, the sample with insufficient material and the result that could not be confirmed by digital PCR were also excluded. True and false positive or negative results are reported in Table 4. We conclude to a positive predictive value (PPV) of 100% and a negative predictive value (NPV) of 93% for BRAF V600E detection with IHC, a PPV and NPV of both 100% for \( \text{BRAF} \) mutation detection with Idylla.

Performance of the Idylla system for NRAS testing

\( \text{BRAF} \) and \( \text{NRAS} \) mutations are mutually exclusive in treatment naïve patients \([2, 25]\). Therefore, in our routine practice, we only perform \( \text{NRAS} \) sequencing for \( \text{BRAF} \) wt samples. Only the 42 \( \text{BRAF} \) wild type samples of this study cohort were sequenced for \( \text{NRAS} \) exon 2 and 3 mutations. Contributive results were obtained for 41 samples. The sample which failed for \( \text{NRAS} \) analysis also failed for \( \text{BRAF} \) sequencing. Considering the Idylla system, with \( \text{BRAF} \) and \( \text{NRAS} \) mutation detection being carried out on the same cartridge, as mentioned above, all 65 samples underwent a test but one cartridge failed to run and one test failed due to insufficient material (2/65; 3.1).

Fig 2. A representative BRAF IHC/In-house testing discordant case. Hematoxylin & eosin stained section (A) Some tumor cells admixed with numerous melanophages (arrow) harbor a weak/moderate BRAF immunostaining with DAB (B) which disappears with AEC (C).

https://doi.org/10.1371/journal.pone.0221123.g002
NRAS mutations were found in 20 out of the 41 valid samples (48.7%) with Sanger sequencing and 15 out of the 63 (23.8%) with Idylla or in 15 out of the 41 (36.6%) if we focus on samples that had been sequenced (Table 2). As expected, no NRAS mutations were found with Idylla on samples bearing a BRAF mutation. Three common alterations (2 Q61R mutations and 1 Q61L mutation) were found by sequencing but not by the Idylla system. Sanger sequencing also highlighted two mutations not covered by Idylla PCR probes: one complex mutation (Q61_E62delinsHK) and one rare variant of unknown clinical significance (G60E). Conversely, the NRAS-BRAF_EGFR S492R cartridge was initially designed for colorectal cancers and also screens NRAS exon 4. No alteration of this exon was detected with the cartridges.

Taking into account only the mutations tested by all approaches, the overall agreement between Sanger sequencing and Idylla NRAS-BRAF-EGFR S492R Mutation Assay was 92.1% (35/38).

Considering NRAS results, 3 discordances were observed between Sanger sequencing and Idylla (Table 3). These discrepancies were also investigated using digital PCR. Results are detailed in Table 3 and digital PCR data are presented in Fig 1. The DNA sequencing data were all confirmed by digital PCR. Therefore, we conclude that 3 false NRAS negative results were obtained with the Idylla cartridge (Fig 1C).

Table 3. Discordant genotyping results.

| Sample number | Tumor area (mm²) | In-house assay | Idylla | IHC | Digital PCR (VAF%) | Conclusion |
|---------------|------------------|----------------|--------|-----|-------------------|------------|
| 25            | 9                | BRAF V600E     | BRAF V600 | BRAF Neg | BRAF V600E (30%) | IHC false negative result |
| 49            | 50               | BRAF V600E     | BRAF V600 | BRAF Neg | BRAF V600E (48%) | IHC false negative result |
| 60            | 35               | BRAF V600E     | BRAF V600 | BRAF Neg | BRAF V600E (32%) | IHC false negative result |
| 23            | 190              | BRAF V600X*    | WT     | BRAF Pos | DNA degraded, Digital PCR failure | Not conclusive |

* Nucleotide characterization by Sanger sequencing failed

Table 4. Performance of BRAF and NRAS testing by IHC and Idylla compared to in-house assay.

|                        | BRAF IHC | BRAF Idylla | NRAS Idylla |
|------------------------|----------|-------------|-------------|
| True positive          | 14       | 21          | 15          |
| False positive         | 0        | 0           | 0           |
| True negative          | 38       | 41          | 20          |
| False negative         | 3        | 0           | 3           |
| Total                  | 55       | 62          | 38          |

Positive Predictive Value: 100% 100% 100%

Negative Predictive Value: 93% 100% 87%
In summary, true and false positive and negative results are reported in Table 4. We conclude to a PPV and NPV of 100% and 87% respectively, for NRAS mutation detection using the Biocartis cartridges.

Discussion

For our routine clinical practice, we have developed a workflow for molecular analysis of tumor samples from metastatic melanoma [26–28]. Using these tests, over the past 5 years, we have tested 1920 melanoma samples. Our laboratory is accredited in accordance with the International Standard ISO15189. The turnaround time (TAT) is usually between 3 and 7 days since the tests are performed once a week. Recently, rapid screening methods have emerged. These are designed to be used as soon as a sample is available, thus reducing the TAT. In this study we compared the performance of two of these rapid methods for the detection of mutations in melanoma samples.

BRAF immunohistochemistry is based on the use of the VE1 antibody, which only detects the BRAF V600E mutation [10]. BRAF IHC is presented as a pre-screening tool, allowing the rapid introduction of a treatment based on BRAF inhibitors [13, 29]. This is only feasible if the PPV is of 100%. In our prospective study, IHC yielded a final PPV of 100% and a NPV of 93% when calculated with V600E mutated samples only. Three tests were confirmed as false negative. This has already been described [16, 30]. In a routine workflow, negative samples would be further investigated using DNA-based techniques for other BRAF V600 mutations, which have also been shown to drive clinical benefit from BRAF inhibitors. In the initial analysis, 3 tests were false positive. This was linked to a technical error involving use of the wrong chromogen, and for this reason they were then considered as true negative. However it is important to point out that the interpretation based on IHC can be difficult, especially when the number of tumor cells is very low or when heterogeneous staining is observed [13, 15]. When focusing on these particular stains, the PPV of BRAF IHC dropped to 70% in the study performed by Tetzlaff et al. [15]. Hence, the vast majority of these studies recommend addressing equivocal or low sample staining for DNA-based molecular testing [13, 15, 29]. Furthermore, since NRAS testing is also of importance, procedures allowing the simultaneous analysis of both BRAF and NRAS are attractive.

In the current study, we also evaluated the Idylla platform. This is a fully automated real-time PCR-based system, capable of detecting most clinically relevant mutations. We tested the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges, originally designed for colorectal cancer, but also of interest for melanoma as it enables, in a single 2-hour run without any sample pre-treatment, the qualitative detection of 5 mutations in codon 600 of the BRAF gene, 18 mutations in codons 12, 13, 59, 61, 117 and 146 of the NRAS gene and 2 mutations in codon 492 of the EGFR gene. After exclusion of the mutations not tested by all techniques and various technical failures, the Idylla NRAS-BRAF-EGFR S492R Mutation Assay displayed a PPV and NPV of 100% for BRAF mutation assessment. The assay was less accurate for the detection of NRAS mutations since the final PPV was 100%, but the NPV was 87%. This lower NPV result was due to 3 false negative results. These samples were confirmed by dPCR to harbor two NRAS Q61R mutations and one NRAS Q61L mutation at allele frequencies of 15%, 17% and 58%, which is above the expected sensitivity of the Idylla NRAS-BRAF-EGFR S492R Mutation Assay (ranging between 1 and 5% depending on the mutation). The tumor cell content of these samples was comprised between 25% and 50% for 2 samples, and above 50% for the third one. Tumor areas loaded into the cartridges were 32, 42 and 60 mm², which is in the range of what is recommended by the manufacturer (25–300 mm² for 10-μm sections).
Three previous studies reported their results using the NRAS-BRAF-EGFR or NRAS-BRAF Mutation Assay in colorectal cancer [21, 22, 31] and one in metastatic melanoma [20]. These evaluations were conducted on archival FFPE samples selected according to size and mutational status. Three found a complete agreement of BRAF results with NGS results [20, 21] or MassARRAY [22] and the only multicenter and multi-molecular method evaluation found 2 false positives (2 of 322 negative samples; n = 410; PPV 98%; NPV 99%) [31]. Considering NRAS results, the same study reported 1 false positive (1/319) and 4 false negative results (4/94), including two samples that were finally excluded from the performance analysis as the allele frequency obtained with the confirmation method was under the LOD of the Idylla system. In other monocenter studies, when compared to NGS and Mass Array [20–22], the Idylla system demonstrated a greater or similar sensitivity. However, Barel et al. noticed one difference in mutation genotyping since NGS highlighted an NRAS G13C mutation confirmed by SNaPshot whereas the Idylla cartridges, which do not search the G13C alteration, reported a NRAS G12A.

Though Idylla BRAF analysis confirmed through these results and our own study to be sensitive and quite specific, we reported an inferior sensitivity of NRAS mutation detection, also observed in the Prieto-Potin team results, though to a lesser extent. As hypothesized by Barel et al. [20], NRAS alterations are more numerous than BRAF alterations and primer multiplexing is probably more challenging for a fully automated system requiring the use of stringent internal cut-off which could lead to a decreased sensitivity. The reason for our greater lack of sensitivity is probably due to the prospective nature of our cohort, and to the absence of any selection bias. All the samples collected were tested, independently of their size. By contrast for instance, to select 235 archival FFPE samples, Johnston et al. excluded 11 samples for insufficient material and 8 because the tumor area did not meet the Idylla criteria [22].

The tumor area required to use the cartridges is 50–600 mm² of 5-μm FFPE sections. If we had strictly applied these requirements, 23 samples out of 65 (35.4%) would have been excluded from our cohort. In routine practice, additional tissue sections (when possible) or alternative techniques would have been necessary. It should be noted that concordant results have been obtained on samples with lower amounts of material than the requirements, but in a context of a certified laboratory, the use of a reagent outside the manufacturer’s protocol should be strongly validated and documented.

Besides the tumor area, a second major limitation is the impossibility to collect DNA from the cartridge after test completion. In our study, 11 out the 65 patients required a KIT gene analysis. Thereby more sample sections would have been necessary for further molecular analysis consuming more material on sometimes small samples. Moreover, in the event of assay failure, one or more new FFPE sections would be necessary. Johnston et al. had to repeat up to 4 cartridges (4/235; 1.74%) after instrument errors [21, 22].

Finally, cost issues are an important factor. Several studies have demonstrated that the Idylla platform has the shortest hands-on time compared to conventional molecular methods [32]. The cost of an Idylla NRAS-BRAF Mutation test was about €216 in France in 2017 [33], with almost no labor cost. We evaluated the overall cost of our routine tests at €36 (reagents €21; labor 15€). Bisschop et al. [32] estimated the cost of reagents for different techniques (list prices not including salary and equipment): in-house methods HRM/Sanger (€175), Next Generation sequencing (€275), ddPCR (€45) and BRAF IHC (€122). IHC only identifies the BRAF V600E mutation, whereas dPCR (using multiplex assays or as separate reactions with different probes) and Idylla can be used to detect the most common BRAF mutations. NGS provides a larger molecular profile of targetable biomarkers. Hence the ratio cost/information provided should be analyzed carefully.
With a very easy laboratory implementation and a fast turnaround time, the Idylla system is an attractive tool for fast therapeutic marker detection, especially for rapidly progressive patients. Nevertheless, the Idylla NRAS-BRAF-EGFR S492R Mutation Assay has demonstrated a limited sensitivity for the detection of some NRAS mutations and the material requirement could be problematic for small tissue fragments, compromising the opportunity of additional molecular tests. We concluded that the Idylla NRAS-BRAF-EGFR S492R Mutation Assay should not be a substitute for traditional molecular methods in a conventional therapeutic patient care process without the expertise needed to have a critical view of the produced results.

Supporting information

S1 Table. Characteristics of the 65 samples tested with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges. Tumor areas were measured using the open source ImageJ software.

(XLSM)

Acknowledgments

We are most grateful to Paola Valente and David Dejans (Biocartis) for fruitful discussions during the course of this study. The cartridges used were generously provided free of charge by Biocartis.

Author Contributions

Conceptualization: Audrey Vallée, Céline Bossard, Marc G. Denis.

Data curation: Audrey Vallée, Guillaume Herbreteau, Marc G. Denis.

Formal analysis: Audrey Vallée, Marie Denis-Musquer, Guillaume Herbreteau, Sandrine Théoleyre, Marc G. Denis.

Investigation: Audrey Vallée, Céline Bossard, Marc G. Denis.

Methodology: Audrey Vallée, Marie Denis-Musquer, Sandrine Théoleyre, Céline Bossard, Marc G. Denis.

Project administration: Marc G. Denis.

Resources: Marie Denis-Musquer, Guillaume Herbreteau.

Supervision: Marc G. Denis.

Validation: Audrey Vallée, Sandrine Théoleyre, Céline Bossard, Marc G. Denis.

Writing – original draft: Audrey Vallée, Marc G. Denis.

Writing – review & editing: Marie Denis-Musquer, Guillaume Herbreteau, Sandrine Théoleyre, Céline Bossard, Marc G. Denis.

References

1. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395–406. https://doi.org/10.1016/j.molonc.2007.12.003 PMID: 19383313

2. Colombino M, Capone M, Lissia A, Cosso A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30: 2522–9. https://doi.org/10.1200/JCO.2011.41.2452 PMID: 22614978
3. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol 2016; 34: 871–8. https://doi.org/10.1200/JCO.2015.62.9345 PMID: 26811525

4. Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 2017; 28: 2581–7. https://doi.org/10.1093/annonc/mdx339 PMID: 28961848

5. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014; 20: 1965–77. https://doi.org/10.1158/1078-0432.CCR-13-3122 PMID: 24463458

6. Hepp MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer 2017; 17: 536. https://doi.org/10.1186/s12885-017-3529-5 PMID: 28797232

7. Arozarena I, Wellbrock C. Overcoming resistance to BRAF inhibitors. Ann Transl Med 2017; 5: 387. https://doi.org/10.21037/atm.2017.06.09 PMID: 29114545

8. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationaly activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31: 3182–90. https://doi.org/10.1200/JCO.2012.47.7836 PMID: 23775962

9. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol 2018;

10. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, et al. Immunohistological testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223–33. https://doi.org/10.1007/s00401-011-0887-y PMID: 22012135

11. Anderson S, Bloom KJ, Vallera DU, Rueschhoff J, Meldrum C, Schilling R, et al. Performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012; 136: 1385–91. https://doi.org/10.5858/arpa.2011-0505-OA PMID: 22332713

12. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis MG. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 2004; 18: 349–52. https://doi.org/10.1016/j.mcp.2004.05.004 PMID: 15294323

13. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013; 15: 94–100. https://doi.org/10.1016/j.jmoldx.2012.09.001 PMID: 23159108

14. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Investig Dermatol 2015; 135: 908–15. https://doi.org/10.1038/jid.2014.366 PMID: 25145878

15. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, et al. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. J Pathol 2015; 237: 156–66. https://doi.org/10.1002/path.4408 PMID: 26058727

16. Pearlstein MV, Zedek DC, Ollila DW, Treacea A, Gulley ML, Groben PA, et al. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol 2014; 41: 724–32. https://doi.org/10.1111/j.1600-0425.2013.01556.x PMID: 24917033

17. Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragon E, et al. Multi-center evaluation of the novel fully-automated PCR-based Idylla BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. J Cutan Pathol 2015; 42: 746–50. https://doi.org/10.1111/j.1600-0425.2014.01821.x PMID: 24917033

18. Harle A, Salleron J, Franchuz C, Dubois C, Filhine-Tressarie P, Leroux A, et al. Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma. PLoS One 2016; 11: e0153576. https://doi.org/10.1371/journal.pone.0153576 PMID: 27111917

19. Schiefer AI, Parlow L, Gabler L, Mesteri I, Koperek O, von Deimling A, et al. Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn 2016; 18: 370–7. https://doi.org/10.1016/j.jmoldx.2015.12.005 PMID: 26921540

20. Barel F, Guibourg B, Lambros L, Le Flahet G, Marcorelles P, Uguen A. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. Acta Derm Venereol 2018; 98: 44–9. https://doi.org/10.2340/00015555-2738 PMID: 28660280
21. Colling R, Wang LM, Soilleux E. Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC. J Clin Pathol 2017; 70: 610–4. https://doi.org/10.1136/jclinpath-2017-204356 PMID: 28292978

22. Johnston L, Power M, Sloan P, Long A, Silmon A, Chaffey B, et al. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. J Clin Pathol 2017; 71: 336–43. https://doi.org/10.1136/jclinpath-2017-204629 PMID: 28899979

23. Quereux G, Herbreteau G, Knol AC, Valle A, Khammari A, Theoleyre S, et al. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. BMC Res Notes 2017; 10: 320. https://doi.org/10.1186/s13104-017-2650-5 PMID: 28743309

24. Theoleyre S, Masson I, Herbreteau G, Valle A, Senellart H, Denis MG. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid. Lung Cancer 2017; 114: 111–2. https://doi.org/10.1016/j.lungcan.2017.010 PMID: 29096978

25. Curtin JA, Fridyard J, Kageshita T, Patel HK, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135–47. https://doi.org/10.1056/NEJMoa050092 PMID: 16291983

26. Wyilmanski S, Denis MG, Theoleyre S, Bouquin R, Valle A, Knol AC, et al. BRAF mutations might be more common than supposed in vulvar melanomas. Exp Dermatol 2018; 27: 210–3. https://doi.org/10.1111/exd.13472 PMID: 29178146

27. Knol AC, Pandolfino MC, Valle A, Nguyen F, Lella V, Khammari A, et al. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma. Exp Dermatol 24: 70–3. https://doi.org/10.1111/exd.12584 PMID: 25363723

28. Saint-Jean M, Quereux G, Nguyen JM, Peuvrel L, Brocard A, Valle A, et al. Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. Oncol Rep 32: 806–14. https://doi.org/10.3892/or.2014.3265 PMID: 24926836

29. Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. J Surg Res 2016; 203: 407–15. https://doi.org/10.1016/j.jss.2016.04.026 PMID: 27363650

30. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37: 61–5. https://doi.org/10.1097/PAS.0b013e31826485c0 PMID: 23026937

31. Prieto-Potin I, Montagut C, Bellosillo B, Evans M, Smith M, Melchior L, et al. Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. J Mol Diagn 2018; 20: 664–76. https://doi.org/10.1097/CMR.0000000000000421 PMID: 29232304

32. Bisschop C, Ter Eist A, Bosman LJ, Platteel I, Jalving M, van den Berg A, et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. Melanoma Res 2018; 28: 96–104. https://doi.org/10.1097/MCR.0000000000000421 PMID: 29232304

33. Le Flahet G, Guibourg B, Marcouilles P, Uguen A. Financial implications of Idylla testing in colorectal cancer, lung cancer and melanoma: a French laboratory point of view. J Clin Pathol 2017; 70: 906–7. https://doi.org/10.1136/jclinpath-2017-204579 PMID: 28798207